We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amneal Pharmaceuticals Holding Co | NYSE:AMRX | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.87 | 0 | 01:00:00 |
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its third quarter 2019 financial results on Wednesday, November 6, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on November 6, 2019.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at https://investors.amneal.com. The webcast can also be accessed at the following URL: https://event.on24.com/wcc/r/2080000/0FFBE4DA8E819349A7FE463FEA182A89.
To access the call through a conference line, dial (844) 746-0741 (in the U.S.) and (412) 317-5273 (international callers).
A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (877) 344-7529 (in the U.S.) and (412) 317-0088 (international callers). The access code for the replay is 10135886.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal has an extensive portfolio of more than 300 generic medicines and is expanding its portfolio to include complex dosage forms in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system disorders and parasitic infections. For more information, visit www.amneal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005362/en/
Mark Donohue (908) 409-6718 www.amneal.com
1 Year Amneal Pharmaceuticals Chart |
1 Month Amneal Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions